Laseroptek, a company specializing in laser devices for skin beauty and dermatologic disease treatment, announced on the 10th that it has obtained item approval from the Ministry of Food and Drug Safety for its new product, Baseukyura589.


Baseukyura589. Laser Optek

Baseukyura589. Laser Optek

View original image

Baseukyura589 is the world's first solid-state vascular treatment laser device that implements a 589-nanometer wavelength based on Raman technology. It is designed for broad use not only in treating vascular skin diseases such as hemangioma, port-wine stains, rosacea, and facial flushing, but also in various vascular pigment treatments and aesthetic procedures including melasma, hyperpigmentation, and toning. Compared with conventional pulsed dye lasers, it enhances output stability and improves maintenance efficiency by eliminating the need for consumable dye replacement, thereby increasing both clinical safety and treatment efficiency.


Laseroptek regards Baseukyura589 as a "10-year growth engine" that will drive its mid- to long-term expansion. The company plans to first establish Baseukyura589 successfully in the disease treatment market and then expand its scope into the aesthetic dermatology market. It is currently undergoing the approval process with the U.S. Food and Drug Administration (FDA), and global market entry is expected to become visible as early as the second half of this year.



Lee Changjin, CEO of Laseroptek, said, "Baseukyura589 is an innovative device that will present a new paradigm in the vascular treatment market," adding, "Even at this stage, as we prepare for its launch with technology that can overcome the limitations of existing pulsed dye lasers, there is already strong interest from the medical community both in Korea and overseas."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing